331920 Stock Chart & Stats
₩9370.00
-₩550.00(-5.54%)
―
--
Day’s Range― - ―
52-Week Range₩2,535.00 - ₩19,840.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)47.55K
Market Cap
₩104.77B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.41
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,181,555
10 Day Avg. Volume42,921
30 Day Avg. Volume47,546
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1,773,861.97
Revenue Forecast (FY)₩40.82T
331920 FAQ
What was Celemics, Inc.’s price range in the past 12 months?
Celemics, Inc. lowest stock price was ₩2535.00 and its highest was ₩19840.00 in the past 12 months.
What is Celemics, Inc.’s market cap?
Celemics, Inc.’s market cap is ₩104.77B.
When is Celemics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Celemics, Inc.’s earnings last quarter?
Currently, no data Available
Is Celemics, Inc. overvalued?
According to Wall Street analysts Celemics, Inc.’s price is currently Undervalued.
Does Celemics, Inc. pay dividends?
Celemics, Inc. does not currently pay dividends.
What is Celemics, Inc.’s EPS estimate?
Celemics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Celemics, Inc. have?
Celemics, Inc. has 11,181,555 shares outstanding.
What happened to Celemics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Celemics, Inc.?
Currently, no hedge funds are holding shares in KR:331920
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Genexine, Inc.
―
Aptabio Therapeutics, Inc.
―
ViGenCell, Inc.
―
TiumBio Co., Ltd.
―
VUNO Inc.
―